Круглосуточно
+7 (965) 177 17 74

бесплатно по России

цаталодж 3062803 ?сгов_ревиев=3076579

During the fighting near Izyum in the spring of 2022, military Mikhail Yurchuk received a complex wound. As a result, the man lost an arm and a leg. First, he was fitted with a prosthetic leg, and recently at the Lviv National Rehabilitation Center "Indestructible" - a modern bionic prosthetic arm. Thanks to special sensors, it can reproduce familiar movements. Now the warrior is undergoing rehabilitation. This was reported in the First TMO Lviv.

5-ASA preparations have very weak immunosuppressive activity. There are no reports that these drugs are associated with an increased risk of infection, and studies evaluating the safety profile of 5-ASA do not show an increased risk of serious or opportunistic infections. Treatment with 5-ASA should be continued without concern for an increased risk of infection or severe COVID-19. If the patient is in contact with a patient with COVID-19 or develops COVID-19, treatment with 5-ASA should be continued.

Ингибиторы JAK ( тофацитиниб и др.) селективно влияют на внутриклеточную сигнальную систему JAK/STAT, опосредующую действие многих цитокинов, участвующих в патогенезе неспецифического язвенного колита. В отличие от генно-инженерных биологических препаратов, ингибиторы янус-киназа представляют собой низкомолекулярные синтетические средства, предназначенные для перорального приема. Тофацитиниб рекомендуют назначать пациентам с тяжелым и среднетяжелым течением неспецифического язвенного колита. Ингибиторы JAK могут нарушать вирусный иммунитет. Рекомендуется использовать низкую эффективную дозу для поддержания ремиссии: по возможности 5 мг, вместо 10 мг, два раза в день. Избегайте применения тофацитиниба во время пандемии, если нет других альтернатив. Это позволит пациентам избежать возможных побочных эффектов и частого наблюдения за патологией.

Back in 2002, according to the justification of the Institute, inactivated polio vaccine (IPV) was introduced into the Immunization Calendar of Ukraine for the 1st vaccination against poliomyelitis (children continued to receive OPV for the remaining 5 doses by age). In 2006, this vaccine was also used for the second vaccination. This made it possible to first reduce and then practically stop the cases of vaccine-associated paralytic poliomyelitis in Ukraine. Since then, the issue of switching to a full IPV vaccination scheme in Ukraine has been repeatedly raised, as has been practiced for many years in all European countries, the USA, Canada, and Australia. Currently, this problem is becoming even more urgent, given both the epidemic situation and the prospects for Ukraine's accession to the EU.

Быстрая запись на прием

Ваше имя:* Телефон:* Выберите специализацию:* Выберите врача:

Дополнительная информация: